<DOC>
	<DOC>NCT02863705</DOC>
	<brief_summary>The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN速 (brimonidine tartrate/timolol malate) in patients only using COMBIGAN速 (brimonidine tartrate/timolol malate) and also in patients who require additional IOP lowering with LUMIGAN速 (bimatoprost) 0.01%.</brief_summary>
	<brief_title>Efficacy and Safety of COMBIGAN速 in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Low Tension Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients with Primary open angle glaucoma (Regardless of Intraocular pressure) Previous history of topical betablocker use and insufficiently controlled IOP Pigmentary or exfoliative glaucoma History of angleclosure or an occludable angle by gonioscopy Prior filtration or laser iridotomy Argon laser trabeculoplasty or Selective laser trabeculoplasty performed less than 6 months History or signs of chronic inflammatory eye disease, ocular trauma, or potentially progressive retinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>